SCYNEXIS, Inc. (SCYX)

Market Cap	63.25M
Revenue (ttm)	135.87M
Net Income (ttm)	72.20M
Shares Out	37.21M
EPS (ttm)	1.42
PE Ratio	1.20
Forward PE	2.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,147
Open	1.66
Previous Close	1.68
Day's Range	1.65 - 1.72
52-Week Range	1.15 - 3.87
Beta	2.12
Analysts	Strong Buy
Price Target	13.00 (+664.71%)
Earnings Date	Nov 13, 2023

About SCYX

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technolo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 2, 2014
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: SCYX

Financial Performance

In 2022, SCYNEXIS's revenue was $5.09 million, a decrease of -61.32% compared to the previous year's $13.16 million. Losses were -$62.81 million, 91.1% more than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for SCYX stock is "Strong Buy." The 12-month stock price forecast is $13.0, which is an increase of 664.71% from the latest price.

Price Target

$13.0

(664.71% upside)

Analyst Consensus: Strong Buy